Scholarlink

Background <p>Obesity remains a global health challenge, with limited therapeutic options. Berberine (BBR) shows promise as an anti-obesity agent. However, its clinical application is hampered by modest efficacy and poor bioavailability.</p> Objective <p>This study investigated the anti-obesity effects and underlying mechanisms of B12, a novel BBR derivative with enhanced solubility and bioavailability.</p> Methods <p>Mice with obesity induced by a high-fat-diet were employed to evaluate B12’s effect on weight loss. Energy expenditure was assessed using metabolic cages. Adipose tissue morphology was examined through histological analysis. In vitro studies were conducted using 3T3-L1 preadipocytes and immortalized brown adipocytes. Gene and protein expression were analyzed using RT-qPCR, western blotting, and immunohistochemistry. Cell cycle progression was evaluated by flow cytometry.</p> Results <p>B12 demonstrated anti-obesity efficacy superior to BBR, manifesting through dual mechanisms. It enhanced energy expenditure by increasing brown adipocyte numbers and UCP1 expression through SIRT1 upregulation and AMPK phosphorylation. Furthermore, B12 markedly reduced the mass of white adipose tissue in mice with HFD-induced obesity and inhibited adipocyte differentiation and lipid accumulation in 3T3-L1 preadipocytes. This effect was achieved through intervention at multiple stages: early-stage downregulation of CyclinD1 and C/EBPβ, followed by reduced expression and heterodimerization of RXRα and PPARγ during middle and late stages of differentiation, collectively preventing matural adipocyte formation.</p> Conclusions <p>Our findings establish B12 as a promising anti-obesity agent, offering significantly enhanced efficacy over its parent compound BBR. This natural product-derived therapeutic candidate, with its improved pharmacological properties and dual mechanism of action, represents a significant advance in phytomedicine-based approaches to obesity treatment.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel berberine derivative B12 exhibits superior anti-obesity effects via targeting brown and white adipocyte dynamics

  • 期刊论文

  • 发表日期：

    2026年7月4日

查看全文
  • Wenqing Zhang,
  • Yanhong Feng,
  • Chunyi Gao,
  • Linhai Zhong,
  • Wenjun Wang,
  • Minying Xu,
  • Bowen Zheng,
  • Yuehua Zhang,
  • Shengyu Wang,
  • Shaoxiong Yi,
  • Zufang Wu,
  • Yongqing Lin,
  • Beibei Xu,
  • Sijie Cheng,
  • Yan-yan Zhan,
  • Shaoliang Zhang,
  • Xiaoting Hong,
  • Tianhui Hu

摘要

Background

Obesity remains a global health challenge, with limited therapeutic options. Berberine (BBR) shows promise as an anti-obesity agent. However, its clinical application is hampered by modest efficacy and poor bioavailability.

Objective

This study investigated the anti-obesity effects and underlying mechanisms of B12, a novel BBR derivative with enhanced solubility and bioavailability.

Methods

Mice with obesity induced by a high-fat-diet were employed to evaluate B12’s effect on weight loss. Energy expenditure was assessed using metabolic cages. Adipose tissue morphology was examined through histological analysis. In vitro studies were conducted using 3T3-L1 preadipocytes and immortalized brown adipocytes. Gene and protein expression were analyzed using RT-qPCR, western blotting, and immunohistochemistry. Cell cycle progression was evaluated by flow cytometry.

Results

B12 demonstrated anti-obesity efficacy superior to BBR, manifesting through dual mechanisms. It enhanced energy expenditure by increasing brown adipocyte numbers and UCP1 expression through SIRT1 upregulation and AMPK phosphorylation. Furthermore, B12 markedly reduced the mass of white adipose tissue in mice with HFD-induced obesity and inhibited adipocyte differentiation and lipid accumulation in 3T3-L1 preadipocytes. This effect was achieved through intervention at multiple stages: early-stage downregulation of CyclinD1 and C/EBPβ, followed by reduced expression and heterodimerization of RXRα and PPARγ during middle and late stages of differentiation, collectively preventing matural adipocyte formation.

Conclusions

Our findings establish B12 as a promising anti-obesity agent, offering significantly enhanced efficacy over its parent compound BBR. This natural product-derived therapeutic candidate, with its improved pharmacological properties and dual mechanism of action, represents a significant advance in phytomedicine-based approaches to obesity treatment.